Convicted Importer Banned: Oppenheimer Out for Five Years
Published Date: 10/1/2025
Notice
Summary
Jason Oppenheimer is banned for 5 years from importing any drugs into the U.S. because he was convicted of a serious crime involving illegal drugs. He didn’t respond to the FDA’s notice, so the ban starts officially and there’s no chance for a hearing. This means no drug imports from him until July 17, 2025, protecting public safety and keeping things legal.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Five-year drug import ban
The FDA has barred Jason Oppenheimer for 5 years from importing or offering for import any drug into the United States. The order is based on his federal felony conviction for possession with intent to distribute Tapentadol. Because he did not request a hearing and had not responded as of July 17, 2025, he waived his right to a hearing.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-19161 — Eagle Creek Reusens Hydro, LLC; Notice Of Reasonable Period of Time for Water Quality Certification Application
Eagle Creek Reusens Hydro, LLC asked Virginia’s environmental agency for permission to make sure their project keeps water clean. Virginia has one year, until August 27, 2026, to approve or deny this request. If they don’t decide by then, their say is automatically skipped, letting the project move forward without that approval.
Next: 2025-19163 — Yong Sheng Jiao: Denial of Application for Termination of Debarment
The FDA has decided not to end Yong Sheng Jiao’s ban from certain activities under the law. Mr. Jiao was told he could ask for a hearing to explain why the ban should stop, but he chose not to. This means his ban stays in place, and no money or timing changes are involved right now.